171 related articles for article (PubMed ID: 22072157)
1. Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment.
Panossian Z; Drury PL; Cundy T
Diabetologia; 2012 Jan; 55(1):267-9. PubMed ID: 22072157
[No Abstract] [Full Text] [Related]
2. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
Pettus J; McNabb B; Eckel RH; Skyler JS; Dhalla A; Guan S; Jochelson P; Belardinelli L; Henry RH
Diabetes Obes Metab; 2016 May; 18(5):463-74. PubMed ID: 26749407
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
[TBL] [Abstract][Full Text] [Related]
4. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
5. Monitoring safety and effectiveness in patients receiving metformin.
Choe HM; Cornish L; Townsend K; Jobe J; Mitrovich S
Am J Health Syst Pharm; 2004 Aug; 61(15):1550-1. PubMed ID: 15372824
[No Abstract] [Full Text] [Related]
6. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
7. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.
Mearns ES; Saulsberry WJ; White CM; Kohn CG; Lemieux S; Sihabout A; Salamucha I; Coleman CI
Diabet Med; 2015 Dec; 32(12):1530-40. PubMed ID: 26104021
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
[TBL] [Abstract][Full Text] [Related]
11. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Del Prato S; Foley JE; Kothny W; Kozlovski P; Stumvoll M; Paldánius PM; Matthews DR
Diabet Med; 2014 Oct; 31(10):1178-84. PubMed ID: 24863949
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
[TBL] [Abstract][Full Text] [Related]
13. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
[TBL] [Abstract][Full Text] [Related]
14. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
Aggarwal N; Singla A; Mathieu C; Montanya E; Pfeiffer AFH; Johnsson E; Zhao J; Iqbal N; Bailey C
Diabetes Obes Metab; 2018 Feb; 20(2):463-467. PubMed ID: 28857388
[TBL] [Abstract][Full Text] [Related]
15. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.
Polidori D; Capuano G; Qiu R
Diabetes Obes Metab; 2016 Apr; 18(4):348-54. PubMed ID: 26661906
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
17. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
Bajaj HS; Ye C; Jain E; Venn K; Stein E; Aronson R
Diabetes Obes Metab; 2018 Jan; 20(1):195-199. PubMed ID: 28640433
[TBL] [Abstract][Full Text] [Related]
18. Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.
Yin J; Deng H; Qin S; Tang W; Zeng L; Zhou B
Diabetes Res Clin Pract; 2014 Sep; 105(3):e10-5. PubMed ID: 25005849
[TBL] [Abstract][Full Text] [Related]
19. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
20. Summaries for patients: Oral drug treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Ann Intern Med; 2012 Feb; 156(3):I36. PubMed ID: 22312157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
